eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Share:
Send email
Share:
abstract:
Original paper

Impact of androgen deprivation therapy in patients with unfavorable intermediate-risk prostate cancer receiving brachytherapy-based dose-escalated radiation therapy

Nikhil T. Sebastian
1
,
Subir Goyal
2
,
Yuan Liu
2, 3
,
Vishal Dhere
1
,
Ashesh B. Jani
1
,
Bruce Hershatter
1
,
Pretesh R. Patel
1
,
Jay W. Shelton
1
,
Sheela Hanasoge
1
,
Karen D. Godette
1
,
Sagar A. Patel
1

  1. Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA
  2. Biostatistics and Bioinformatics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, GA, USA
  3. Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA
J Contemp Brachytherapy 2024; 16
DOI: https://doi.org/10.5114/jcb.2024.143130
Online publish date: 2024/09/20
View full text Get citation
 
Purpose:
While the benefit of short-term androgen deprivation therapy (ADT) has been established for patients with intermediate-risk (IR) prostate cancer (PCa) receiving dose-escalated external beam radiation therapy (EBRT), the role of ADT for patients treated with brachytherapy (BT) with or without supplemental EBRT (sEBRT) is less clear.

Material and methods:
We conducted a single-institution retrospective analysis of men with National Comprehensive Cancer Network (NCCN) unfavorable IR (UIR) PCa. All patients received BT with or without sEBRT, and were stratified by the receipt of 4-6 months of ADT. Kaplan-Meier method was used to measure biochemical progression-free survival (bPFS) between men who did vs. did not receive ADT. Multivariable Cox proportional hazards with backward selection was utilized to determine association of concomitant ADT with bPFS accounting for confounding variables.

Results:
We identified 201 eligible patients treated between 2002 and 2019, 78 (38.8%) of whom received ADT. Median follow-up was 15 years. On univariable analysis, there was no significant association of ADT use with bPFS (HR = 0.95, 95% CI: 0.34-2.63, p = 0.92). Only PSA ≥ 10 was significant for association with worse bPFS (HR = 3.51, 95% CI: 1.29-9.52, p = 0.014). On multivariable analysis, there was no association of ADT use with bPFS (HR = 0.97, 95% CI: 0.34-2.78, p = 0.96).

Conclusions:
Short-course ADT was not associated with improved bPFS in our study among men with UIR PCa treated with BT with or without sEBRT. These findings suggest that dose intensification achieved with BT may alone be sufficient in treating selected patients with UIR disease, but prospective studies are warranted.

keywords:

unfavorable intermediate-risk, prostate cancer, brachytherapy, androgen deprivation therapy

  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.